CR20120009A - 2-indolinonas sustituidas con pirrolos inhibidores de proteinquinasas (divisional exp. 6728) - Google Patents

2-indolinonas sustituidas con pirrolos inhibidores de proteinquinasas (divisional exp. 6728)

Info

Publication number
CR20120009A
CR20120009A CR20120009A CR20120009A CR20120009A CR 20120009 A CR20120009 A CR 20120009A CR 20120009 A CR20120009 A CR 20120009A CR 20120009 A CR20120009 A CR 20120009A CR 20120009 A CR20120009 A CR 20120009A
Authority
CR
Costa Rica
Prior art keywords
proteinquinase
pirrols
indolinones
divisional
exp
Prior art date
Application number
CR20120009A
Other languages
English (en)
Spanish (es)
Inventor
Peng Cho Tang
Todd Miller
Xiaoyuan Li
Li Sun
Chung Chen Wei
Shahrzad Shirazian
Congxin Liang
Tomas Vojkovsky
Asaad S Nematalla
Michael Hawley
Original Assignee
Sugen Inc
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27391578&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20120009(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sugen Inc, Upjohn Co filed Critical Sugen Inc
Publication of CR20120009A publication Critical patent/CR20120009A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Polyurethanes Or Polyureas (AREA)
CR20120009A 2000-02-15 2012-01-09 2-indolinonas sustituidas con pirrolos inhibidores de proteinquinasas (divisional exp. 6728) CR20120009A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18271000P 2000-02-15 2000-02-15
US21642200P 2000-07-06 2000-07-06
US24353200P 2000-10-27 2000-10-27

Publications (1)

Publication Number Publication Date
CR20120009A true CR20120009A (es) 2012-02-07

Family

ID=27391578

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20120009A CR20120009A (es) 2000-02-15 2012-01-09 2-indolinonas sustituidas con pirrolos inhibidores de proteinquinasas (divisional exp. 6728)
CR20120007A CR20120007A (es) 2000-02-15 2012-01-09 2-indolinonas sustituidas con pirrolos inhibidores de proteinquinasas (divisional exp. 6728)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20120007A CR20120007A (es) 2000-02-15 2012-01-09 2-indolinonas sustituidas con pirrolos inhibidores de proteinquinasas (divisional exp. 6728)

Country Status (42)

Country Link
US (4) US6573293B2 (OSRAM)
EP (1) EP1255752B1 (OSRAM)
JP (1) JP3663382B2 (OSRAM)
KR (1) KR100713960B1 (OSRAM)
CN (1) CN1329390C (OSRAM)
AR (1) AR034118A1 (OSRAM)
AT (1) ATE369359T1 (OSRAM)
AU (2) AU2001239770B2 (OSRAM)
BE (1) BE2010C009I2 (OSRAM)
BG (1) BG65764B1 (OSRAM)
BR (2) BRPI0117360B8 (OSRAM)
CA (1) CA2399358C (OSRAM)
CO (1) CO5280092A1 (OSRAM)
CR (2) CR20120009A (OSRAM)
CY (3) CY1108032T1 (OSRAM)
CZ (1) CZ303705B6 (OSRAM)
DE (3) DE122010000004I1 (OSRAM)
DK (1) DK1255752T3 (OSRAM)
EA (1) EA005996B1 (OSRAM)
ES (1) ES2290117T3 (OSRAM)
FR (2) FR08C0002I2 (OSRAM)
HR (1) HRP20020751B1 (OSRAM)
HU (1) HU228979B1 (OSRAM)
IL (1) IL151127A0 (OSRAM)
IS (1) IS2491B (OSRAM)
LT (1) LTC1255752I2 (OSRAM)
LU (2) LU91407I2 (OSRAM)
ME (1) ME00415B (OSRAM)
MX (1) MXPA02008021A (OSRAM)
MY (1) MY130363A (OSRAM)
NL (2) NL300332I2 (OSRAM)
NO (4) NO325532B1 (OSRAM)
NZ (1) NZ520640A (OSRAM)
PE (1) PE20011083A1 (OSRAM)
PL (1) PL211834B1 (OSRAM)
PT (1) PT1255752E (OSRAM)
RS (1) RS50444B (OSRAM)
SI (1) SI1255752T1 (OSRAM)
SK (1) SK287142B6 (OSRAM)
TW (1) TWI306860B (OSRAM)
UA (1) UA73976C2 (OSRAM)
WO (1) WO2001060814A2 (OSRAM)

Families Citing this family (345)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US20040226056A1 (en) * 1998-12-22 2004-11-11 Myriad Genetics, Incorporated Compositions and methods for treating neurological disorders and diseases
MXPA01007099A (es) 1999-01-13 2002-03-27 Univ New York State Res Found Metodo novedoso para disenar inhibidores de la proteina cinasa.
RS50444B (sr) 2000-02-15 2010-03-02 Sugen Inc. Inhibitori 2-indolinon protein kinaze supstituisani pirolom
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
MY128449A (en) 2000-05-24 2007-02-28 Sugen Inc Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
CA2410509A1 (en) 2000-06-02 2001-12-13 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
WO2002002551A1 (en) 2000-06-30 2002-01-10 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
EP1506962B1 (en) 2000-10-20 2008-07-02 Eisai R&D Management Co., Ltd. Nitrogen-containing aromatic heterocycles
CA2432114A1 (en) * 2000-12-20 2002-07-18 Sugen, Inc. 4-(hetero)aryl substituted indolinones
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
JP2004529110A (ja) 2001-03-06 2004-09-24 アストラゼネカ アクチボラグ 脈管損傷活性を有するインドール誘導体
EP1247809A3 (en) * 2001-03-30 2003-12-17 Pfizer Products Inc. Triazine compounds useful as sorbitol dehydrogenase inhibitors
US6599902B2 (en) 2001-05-30 2003-07-29 Sugen, Inc. 5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
CA2452361A1 (en) * 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating autoimmune diseases
IL160097A0 (en) * 2001-08-15 2004-06-20 Upjohn Co Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole 3-ylidene) methyl]2-(dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
AR038957A1 (es) * 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
EP1436259A1 (en) 2001-09-10 2004-07-14 Congxin Liang 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors
WO2003031438A1 (en) * 2001-10-10 2003-04-17 Sugen, Inc. 3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives as kinase inhibitors
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
US7129225B2 (en) * 2001-10-22 2006-10-31 The Research Foundation Of State University Of New York Protection against and treatment of hearing loss
TWI259081B (en) * 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
US20030080191A1 (en) * 2001-10-26 2003-05-01 Allen Lubow Method and apparatus for applying bar code information to products during production
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
US7156308B2 (en) * 2001-12-17 2007-01-02 International Barcode Corporation Double-sided bar code doubling as a single bar code
US20050131733A1 (en) * 2001-12-17 2005-06-16 Allen Lubow Sealable individual bar coded packets
AU2002360753B2 (en) * 2001-12-27 2008-08-21 Theravance, Inc. Indolinone derivatives useful as protein kinase inhibitors
RS70904A (sr) * 2002-02-15 2006-10-27 Pharmacia & Upjohn Company Postupak za dobijanje indolinona
WO2003097854A2 (en) * 2002-05-17 2003-11-27 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
ITMI20021620A1 (it) * 2002-07-23 2004-01-23 Novuspharma Spa Composto ad ativita' antitumorale
WO2004016211A2 (en) * 2002-08-08 2004-02-26 Vanderbilt University Pi3k antagonists as radiosensitizers
JP4588447B2 (ja) * 2002-08-09 2010-12-01 セラヴァンス， インコーポレーテッド 過剰増殖および関連疾患に関連するオンコキナーゼ融合ポリペプチド、これをコードする核酸、ならびにこれを検出する方法および同定する方法
US20040121407A1 (en) * 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
TW200418836A (en) * 2002-09-10 2004-10-01 Pharmacia Italia Spa Formulations comprising an indolinone compound
AU2003302665B2 (en) * 2002-11-15 2009-12-24 Symphony Evolution, Inc. Kinase modulators
AR042042A1 (es) * 2002-11-15 2005-06-08 Sugen Inc Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
US20040209937A1 (en) * 2003-02-24 2004-10-21 Sugen, Inc. Treatment of excessive osteolysis with indolinone compounds
US7452913B2 (en) * 2003-02-24 2008-11-18 Pharmacia & Upjohn Company Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
WO2004076412A2 (en) 2003-02-26 2004-09-10 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
US20040266843A1 (en) * 2003-03-07 2004-12-30 Sugen, Inc. Sulfonamide substituted indolinones as inhibitors of DNA dependent protein kinase (DNA-PK)
US7157577B2 (en) * 2003-03-07 2007-01-02 Sugen Inc. 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors
JPWO2004080462A1 (ja) * 2003-03-10 2006-06-08 エーザイ株式会社 ｃ−Ｋｉｔキナーゼ阻害剤
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10334582A1 (de) * 2003-07-28 2005-02-24 Basf Ag Verfahren zur Herstellung von Maleinsäureanhydrid
WO2005023765A1 (en) * 2003-09-11 2005-03-17 Pharmacia & Upjohn Company Llc Method for catalyzing amidation reactions by the presence of co2
RU2319702C2 (ru) * 2003-10-02 2008-03-20 Фармация Энд Апджон Компани Ллс Негигроскопическая кристаллическая малеатная соль 5-[(z)-(5-фтор-2-оксо-1,2-дигидро-3h-индол-3-илиден)метил]-n-[(2s)-2-гидрокси-3-морфолин-4-илпропил]-2,4-диметил-1h-пиррол-3-карбоксамида, фармацевтическая композиция и способ лечения рака
EP2229955A1 (en) * 2003-10-16 2010-09-22 Imclone LLC Fibroblast growth factor receptor-1 inhibitors and methods of treatment using the same
KR101224410B1 (ko) 2003-11-07 2013-01-23 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 퀴놀리논 화합물을 합성하는 방법
JP4303726B2 (ja) 2003-11-11 2009-07-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 ウレア誘導体およびその製造方法
WO2005053614A2 (en) * 2003-11-26 2005-06-16 The Scripps Research Institute Advanced indolinone based protein kinase inhibitors
WO2005058341A2 (en) * 2003-12-11 2005-06-30 Theravance, Inc. Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
US20050152943A1 (en) * 2003-12-23 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
WO2005118543A1 (ja) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. キナーゼ阻害薬およびその用途
JP2008504292A (ja) 2004-06-24 2008-02-14 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド 免疫増強用の化合物
SE0401790D0 (sv) * 2004-07-07 2004-07-07 Forskarpatent I Syd Ab Tamoxifen response in pre- and postmenopausal breast cancer patients
US20060009510A1 (en) * 2004-07-09 2006-01-12 Pharmacia & Upjohn Company Llc Method of synthesizing indolinone compounds
BRPI0513915A (pt) * 2004-08-26 2008-05-20 Pfizer compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
CN100432071C (zh) * 2004-11-05 2008-11-12 中国科学院上海药物研究所 取代1h－吲哚－2－酮类化合物及其制备方法和用途
GT200500321A (es) * 2004-11-09 2006-09-04 Compuestos y composiciones como inhibidores de proteina kinase.
MX2007011767A (es) * 2005-03-23 2007-10-18 Pfizer Prod Inc Terapia de combinacion de anticuerpo anti-ctla4 e indolinona para el tratamiento del cancer.
CA2763671A1 (en) 2005-04-26 2006-11-02 Pfizer Inc. P-cadherin antibodies
EP1885355A1 (en) * 2005-05-12 2008-02-13 Pfizer, Inc. Anticancer combination therapy using sunitinib malate
NZ563707A (en) 2005-05-18 2011-01-28 Array Biopharma Inc Heterocyclic inhibitors of MEK and methods of use thereof
EP1904480A2 (en) 2005-05-23 2008-04-02 Novartis Pharma AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
RU2007143163A (ru) * 2005-05-26 2009-07-10 Зе Скрипс Ресеч Инститьют (Us) Улучшенные ингибиторы протеинкиназы на основе индолинона
JP5066446B2 (ja) 2005-08-01 2012-11-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を予測する方法
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
MY164457A (en) 2005-09-07 2017-12-15 Amgen Fremont Inc Human monoclonal antibodies to activin receptor-like kinase-1
PL1928858T3 (pl) * 2005-09-19 2009-12-31 Zoetis Services Llc Stałe postacie soli pirolo-podstawionego 2-indolinonu
US20090053236A1 (en) * 2005-11-07 2009-02-26 Eisai R & D Management Co., Ltd. USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
WO2007081560A2 (en) * 2005-12-29 2007-07-19 The Scripps Research Institute Amino acid derivatives of indolinone based protein kinase inhibitors
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
CN101007801A (zh) * 2006-01-27 2007-08-01 上海恒瑞医药有限公司 吡咯取代的2－二氢吲哚酮衍生物、其制法与医药上的用途
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
KR20080110912A (ko) 2006-04-19 2008-12-19 노파르티스 아게 인다졸 화합물 및 ｃｄｃ７의 억제 방법
EP2258700A1 (en) 2006-05-09 2010-12-08 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
CA2652442C (en) * 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
DE102006024834B4 (de) * 2006-05-24 2010-07-01 Schebo Biotech Ag Neue Indol-Pyrrol-Derivate und deren Verwendungen
EP2044939A1 (en) * 2006-06-29 2009-04-08 Eisai R&D Management Co., Ltd. Therapeutic agent for liver fibrosis
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
US20080025946A1 (en) 2006-07-13 2008-01-31 Sivakumar Pallavur V Interleukin 21 and tyrosine kinase inhibitor combination therapy
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
US8044049B2 (en) 2006-08-04 2011-10-25 Takeda Pharmaceutical Company Limited Fused heterocyclic derivative and use thereof
KR101438245B1 (ko) 2006-08-23 2014-09-04 쿠도스 파마슈티칼스 리미티드 Ｍｔｏｒ 억제제로서의 2-메틸모르폴린 피리도-, 피라조- 및 피리미도-피리미딘 유도체
EP2065372B1 (en) * 2006-08-28 2012-11-28 Eisai R&D Management Co., Ltd. Antitumor agent for undifferentiated gastric cancer
JP5568304B2 (ja) 2006-09-15 2014-08-06 タイロジェネクス，インコーポレイテッド キナーゼ阻害剤化合物
KR20170012582A (ko) 2006-11-02 2017-02-02 악셀레론 파마 인코포레이티드 Ａｌｋ１ 수용체 및 리간드 길항제 및 그의 용도
CN101535302A (zh) * 2006-11-06 2009-09-16 株式会社泰丽巴镠斯 新型羟基吲哚衍生物
CN101600718B (zh) 2006-11-06 2013-07-03 特雷罗药物股份有限公司 咪唑并[1,2-b]哒嗪和吡唑并[1,5-a]嘧啶衍生物及其作为蛋白激酶抑制剂的用途
WO2008067756A1 (fr) 2006-12-04 2008-06-12 Jiangsu Simcere Pharmaceutical R & D Co., Ltd. Dérivés de 3-pyrrolo-cyclohexylène-2-dihydro-indolinone et utilisations de ceux-ci
US8962655B2 (en) 2007-01-29 2015-02-24 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
WO2008096218A1 (en) 2007-02-06 2008-08-14 Pfizer Inc. 2-amin0-5, 7-dihydr0-6h- pyrrolo [3, 4-d] pyrimidine derivatives as hsp-90 inhibitors for treating cancer
WO2008114819A1 (ja) 2007-03-20 2008-09-25 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US20090042906A1 (en) * 2007-04-26 2009-02-12 Massachusetts Institute Of Technology Methods for treating cancers associated with constitutive egfr signaling
WO2008138184A1 (fr) 2007-05-14 2008-11-20 Shanghai Hengrui Pharmaceutical Co.Ltd. Dérivés de pyrrolo-azacycles, leur procédé de fabrication et leur utilisation en tant qu'inhibiteurs de protéine kinases
WO2008145398A1 (en) * 2007-06-01 2008-12-04 Pfizer Italia S.R.L. 4-arylpyrrole substituted 2-indoline derivatives active as protein kinase inhibitors
CL2008001626A1 (es) 2007-06-05 2009-06-05 Takeda Pharmaceuticals Co Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
JP5270553B2 (ja) 2007-08-23 2013-08-21 武田薬品工業株式会社 複素環化合物およびその用途
US20090062368A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched sunitinib
CA2736177A1 (en) * 2007-09-06 2009-03-12 Boston Biomedical, Inc. Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
PT2201012E (pt) 2007-10-11 2014-09-04 Astrazeneca Ab Derivados de pirrolo[2,3-d]piridina como inibidores da proteína quinase b
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
US20100256392A1 (en) * 2007-11-21 2010-10-07 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
EP2220072A2 (en) * 2007-11-21 2010-08-25 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
CA2709083A1 (en) * 2007-12-12 2009-06-18 Medichem S.A. Polymorphic forms of a 3-pyrrole substituted 2-indolinone
PT2222675E (pt) 2007-12-19 2013-11-13 Genentech Inc 5-anilinoimidazopiridinas e métodos de utilização
EA201000947A1 (ru) 2007-12-20 2011-02-28 Новартис Аг Производные тиазола, применимые в качестве ингибиторов киназы pi3
ES2387707T3 (es) 2007-12-21 2012-09-28 Genentech, Inc. Azaindolizinas y procedimientos de uso
BRPI0906576A2 (pt) * 2008-01-29 2015-07-07 Eisai R&D Man Co Ltd Composição farmacêutica, kit, uso de um composto, e, agente terapêutico para câncer
EP2113248A1 (en) 2008-04-29 2009-11-04 Ratiopharm GmbH Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide
EP2090306A1 (en) 2008-02-13 2009-08-19 Ratiopharm GmbH Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
EP2240174A1 (en) * 2008-02-13 2010-10-20 Ratiopharm GmbH Pharmaceutical compositions comprising n-ý2-(diethylamino)ethyl¨-5-ý(5-fluoro-1,2- dihydro-2-oxo-3h-indol-3-ylidene)methyl¨-2,4-dimethyl-1h-pyrrole-3-carboxamide
CN101255154B (zh) * 2008-02-18 2011-09-07 靳广毅 一种取代的2-吲哚啉酮衍生物和制备方法及其应用
US20110112164A1 (en) * 2008-02-21 2011-05-12 Generics (Uk) Limited Novel polymorphs and processes for their preparation
EP2098521A1 (en) * 2008-03-06 2009-09-09 Ratiopharm GmbH Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
US20090247767A1 (en) * 2008-03-31 2009-10-01 Teva Pharmaceutical Industries Ltd. Processes for preparing sunitinib and salts thereof
US8466190B2 (en) 2008-04-16 2013-06-18 Natco Pharma Limited Polymorphic forms of Sunitinib base
US8158656B2 (en) * 2008-05-16 2012-04-17 Shenzhen Chipscreen Biosciences Ltd. 2-indolinone derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
US8829039B2 (en) 2008-05-23 2014-09-09 Shanghai Institute Of Pharmaceutical Industry Dihydroindolinone derivatives
WO2009154697A2 (en) 2008-05-28 2009-12-23 Massachusetts Institute Of Technology Disc-1 pathway activators in the control of neurogenesis
AR072117A1 (es) * 2008-06-13 2010-08-04 Medichem Sa Procedimiento para preparar una sal de malato 3-pirrol sustituido 2-indolinona, intermediario de sintesis y una composicion farmaceutica que la comprende.
EP2313396A1 (en) 2008-06-23 2011-04-27 Natco Pharma Limited Process for the preparation of high purity sunitinib and its pharmaceutically acceptable salt
EP2138167A1 (en) 2008-06-24 2009-12-30 ratiopharm GmbH Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
WO2009156837A2 (en) * 2008-06-26 2009-12-30 Medichem, S.A. Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt
US8124649B2 (en) * 2008-06-30 2012-02-28 Cylene Pharmaceuticals, Inc. Oxindole compounds
DE102008031038A1 (de) 2008-06-30 2009-12-31 Alexander Priv.-Doz. Dr. Dömling Sutent zur Anwendung in der Organtransplantation
US20110200612A1 (en) 2008-06-30 2011-08-18 Michael Schuster Treatment of eye diseases and excessive neovascularization using combined therapy
US20110275689A1 (en) * 2008-07-02 2011-11-10 Generics [Uk] Limited Preparation of 3-Pyrrole Substituted 2-Indolinone Derivatives
CA2730079A1 (en) * 2008-07-10 2010-01-14 Generics [Uk] Limited Processes for the preparation of crystalline forms of sunitinib malate
EP2373642A2 (en) 2008-07-24 2011-10-12 Teva Pharmaceutical Industries Ltd Process for the preparation of sunitinib malate via sunitinib acetate and their polymorphs
CN102164913A (zh) 2008-07-24 2011-08-24 麦迪凯姆股份公司 一种3-吡咯替代的2-吲哚酮苹果酸盐的结晶体形式
US8993615B2 (en) * 2008-08-08 2015-03-31 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
RS54233B1 (sr) 2008-08-25 2015-12-31 Amplimmune Inc. Kompozicije pd-1 antagonista i postupci za njihovu primenu
JP2012500837A (ja) * 2008-08-25 2012-01-12 ジェネリクス・（ユーケー）・リミテッド 新規な結晶型およびその調製方法
US20110263670A1 (en) * 2008-08-25 2011-10-27 Vinayak Gore Novel polymorphs of sunitinib and processes for their preparation
MX2011002250A (es) * 2008-08-25 2011-08-17 Amplimmune Inc Antagonistas de muerte celular programada-1 y métodos de uso de los mismos.
AU2009289062B2 (en) * 2008-09-05 2015-01-22 Hammersmith Imanet Limited Isatin derivatives for use as in vivo imaging agents
CA2735900A1 (en) 2008-09-19 2010-03-25 Medimmune, Llc Antibodies directed to dll4 and uses thereof
AR073807A1 (es) * 2008-10-10 2010-12-01 Medichem Sa Proceso para preparar el malato de sunitinib, sal de un acido mas debil que el malato como compuesto intermediario, y proceso para preparar dicha sal intermediaria.
EP2181991A1 (en) * 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) * 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
US20100222371A1 (en) * 2008-11-20 2010-09-02 Children's Medical Center Corporation Prevention of surgical adhesions
WO2010064611A1 (ja) 2008-12-01 2010-06-10 武田薬品工業株式会社 複素環化合物およびその用途
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
TW201028410A (en) 2008-12-22 2010-08-01 Astrazeneca Ab Chemical compounds 610
AU2009331528A1 (en) 2008-12-23 2011-08-11 Astrazeneca Ab Targeted binding agents directed to alpha5beta1 and uses thereof
EP2373643A4 (en) 2009-01-02 2013-08-07 Hetero Research Foundation NEW SUNITINIB MALATE POLYMORPHS
CA2758030C (en) 2009-01-16 2019-01-08 Exelixis, Inc. Malate salt of n-(4-{[6,7-bis(methyloxy)quin0lin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
CN102365021B (zh) 2009-02-05 2015-07-15 伊缪诺金公司 新型苯并二氮杂*衍生物
CN102307875A (zh) 2009-02-09 2012-01-04 苏伯俭股份有限公司 吡咯并嘧啶基axl激酶抑制剂
TW201035088A (en) 2009-02-27 2010-10-01 Supergen Inc Cyclopentathiophene/cyclohexathiophene DNA methyltransferase inhibitors
WO2010098888A1 (en) * 2009-02-27 2010-09-02 Massachusetts Institute Of Technology Uses of chemicals to modulate gsk-3 signaling for treatment of bipolar disorder and other brain disorders
US8785457B2 (en) 2009-03-13 2014-07-22 Cellzome Limited Pyrimidine derivatives as mTOR inhibitors
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
US20120040955A1 (en) 2009-04-14 2012-02-16 Richard John Harrison Fluoro substituted pyrimidine compounds as jak3 inhibitors
US8530492B2 (en) 2009-04-17 2013-09-10 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
EP2255792A1 (en) 2009-05-20 2010-12-01 Ratiopharm GmbH Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide
US8211901B2 (en) 2009-05-22 2012-07-03 Shenzhen Chipscreen Biosciences Ltd. Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors
EP2264027A1 (en) * 2009-05-27 2010-12-22 Ratiopharm GmbH Process for the preparation of N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
US8389580B2 (en) 2009-06-02 2013-03-05 Duke University Arylcyclopropylamines and methods of use
CN101906076B (zh) 2009-06-04 2013-03-13 深圳微芯生物科技有限责任公司 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
WO2011004200A1 (en) 2009-07-10 2011-01-13 Generics [Uk] Limited Novel pyrrole derivatives
FR2948940B1 (fr) * 2009-08-04 2011-07-22 Servier Lab Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2475648A1 (en) 2009-09-11 2012-07-18 Cellzome Limited Ortho substituted pyrimidine compounds as jak inhibitors
CA2774634A1 (en) 2009-09-16 2011-03-24 Ranbaxy Laboratories Limited Salts of sunitinib
CN102666545B (zh) 2009-10-20 2016-04-06 塞尔卓姆有限公司 作为jak抑制剂的杂环吡唑并嘧啶类似物
EP2499133A2 (en) 2009-11-12 2012-09-19 Ranbaxy Laboratories Limited Process for the preparation of crystalline form i of l-malic acid salt of sunitinib
US8916716B2 (en) 2009-11-19 2014-12-23 Ranbaxy Laboratories Limited Process for the preparation of crystalline form II of L-malic acid salt of sunitinib
LT3279215T (lt) 2009-11-24 2020-04-10 Medimmune Limited Tiksliniai surišantys agentai prieš b7-h1
JP2013512859A (ja) 2009-12-03 2013-04-18 大日本住友製薬株式会社 トール様受容体（ｔｌｒ）を介して作用するイミダゾキノリン
WO2011095802A1 (en) 2010-02-02 2011-08-11 Generics [Uk] Limited Hplc method for analyzing sunitinib
WO2011100325A2 (en) * 2010-02-09 2011-08-18 Sicor Inc. Polymorphs of sunitinib salts
EP2533810B1 (en) 2010-02-10 2016-10-12 ImmunoGen, Inc. Cd20 antibodies and uses thereof
CN102762565A (zh) 2010-02-22 2012-10-31 弗·哈夫曼-拉罗切有限公司 吡啶并[3,2-d]嘧啶PI3δ抑制剂化合物及使用方法
WO2011104555A2 (en) 2010-02-25 2011-09-01 Generics [Uk] Limited Novel process
CA2792039A1 (en) 2010-03-04 2011-09-09 Ranbaxy Laboratories Limited Process for the direct preparation of malic acid salt of sunitinib
ES2535116T3 (es) 2010-03-04 2015-05-05 Cellzome Limited Derivados de urea sustituida con morfolino como inhibidores de mtor
CN102858739A (zh) * 2010-03-10 2013-01-02 斯索恩有限公司 酰胺化吡咯甲酸酯化合物的方法
AU2011228765A1 (en) 2010-03-18 2012-10-11 Ranbaxy Laboratories Limited Process for the preparation of malic acid salt of sunitinib
US9162981B2 (en) 2010-03-23 2015-10-20 The Johns Hopkins University Compositions and methods for treatment of neurodegenerative disease
WO2011128699A2 (en) * 2010-04-16 2011-10-20 Generics [Uk] Limited Novel process
EA201291038A1 (ru) 2010-04-30 2013-05-30 Целльзом Лимитид Соединения пиразола в качестве ингибиторов jak
WO2011138565A1 (fr) 2010-05-05 2011-11-10 Biorebus Association pharmaceutique contenant l'acide lipoïque, l'acide hydroxycitrique et une somatostatine a titre de principes actifs
EP2392324A1 (en) 2010-06-01 2011-12-07 Societe De Coordination De Recherches Therapeutiques Rhenium complexes and their pharmaceutical use
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
ES2573515T3 (es) 2010-06-25 2016-06-08 Eisai R&D Management Co., Ltd. Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
US20130143915A1 (en) 2010-07-01 2013-06-06 Cellzome Limited Triazolopyridines as tyk2 inhibitors
RU2571226C2 (ru) 2010-07-09 2015-12-20 Дженентек, Инк. Антитела против нейропилина и способы их применения
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
JP2013534233A (ja) 2010-08-20 2013-09-02 セルゾーム リミティッド 選択的ｊａｋ阻害剤としてのヘテロシクリルピラゾロピリミジン類似体
WO2012027716A1 (en) 2010-08-27 2012-03-01 Collabrx, Inc. Method to treat melanoma in braf inhibitor-resistant subjects
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
US8846953B2 (en) 2010-11-01 2014-09-30 Scinopharm Taiwan, Ltd. Processes for the preparation of 3-(pyrrol-2-yl)methylene)-2-pyrrolones using 2-silyloxy-pyrroles
WO2012059941A1 (en) * 2010-11-04 2012-05-10 Ind-Swift Laboratories Limited Process for preparation of sunitinib malate and salts thereof
WO2012062704A1 (en) 2010-11-09 2012-05-18 Cellzome Limited Pyridine compounds and aza analogues thereof as tyk2 inhibitors
EP2640384A1 (en) 2010-11-18 2013-09-25 Synta Pharmaceuticals Corp. Preselection of subjects for therapeutic treatment with oxygen sensitive agents based on hypoxic status
CA2818612C (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
TWI410425B (zh) 2010-12-03 2013-10-01 Lilly Co Eli 唑并［５，４－ｂ］吡啶－５－基化合物
JP6002149B2 (ja) 2010-12-23 2016-10-05 ネクター セラピューティクス ポリマー−スニチニブコンジュゲート
EP2654797B1 (en) 2010-12-23 2017-11-08 Nektar Therapeutics Polymer-des-ethyl sunitinib conjugates
US8987257B2 (en) 2011-01-31 2015-03-24 Novartis Ag Heterocyclic derivatives
SMT201900181T1 (it) 2011-02-15 2019-05-10 Immunogen Inc Metodi di preparazione di coniugati
DK2675794T3 (da) 2011-02-17 2019-05-06 Cancer Therapeutics Crc Pty Ltd Selektive fak-inhibitorer
ES2691673T3 (es) 2011-02-17 2018-11-28 Cancer Therapeutics Crc Pty Limited Inhibidores de Fak
GB201103578D0 (en) 2011-03-02 2011-04-13 Sabrepharm Ltd Dipyridinium derivatives
US8630703B2 (en) 2011-03-09 2014-01-14 Technion Research & Development Foundation Limited Treatment utilizing hydrophobic weak bases chemotherapeutic agents and illumination
CN102115469A (zh) * 2011-03-21 2011-07-06 浙江大学 吲哚啉-2-酮类衍生物的制备和用途
US20140163023A1 (en) 2011-04-04 2014-06-12 Cellzome Limited Dihydropyrrolo pyrimidine derivatives as mtor inhibitors
EP2694058B1 (en) * 2011-04-08 2015-11-04 Beta Pharma, Inc. New indolinone protein kinase inhibitors
MX2013009931A (es) 2011-04-18 2013-10-01 Eisai R&D Man Co Ltd Agentes terapeuticos contra tumores.
WO2012143320A1 (en) 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
CN102898402B (zh) * 2011-04-26 2016-01-20 北京大学 一种苯并异硒唑酮修饰的吡咯甲酸酯取代的吲哚酮类化合物及其应用
EP2714937B1 (en) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
ES2671748T3 (es) 2011-07-21 2018-06-08 Tolero Pharmaceuticals, Inc. Inhibidores heterocíclicos de proteína quinasas
CN103781780B (zh) 2011-07-28 2015-11-25 赛尔佐姆有限公司 作为jak抑制剂的杂环基嘧啶类似物
WO2013017479A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
EP2739252A4 (en) 2011-08-05 2015-08-12 Forsight Vision4 Inc SMALL MOLECULE ADMINISTRATION USING AN IMPLANTABLE THERAPEUTIC DEVICE
KR20140063700A (ko) 2011-09-20 2014-05-27 셀좀 리미티드 키나제 억제제로서의 피라졸로[4,3-c]피리딘 유도체
RU2616619C2 (ru) 2011-09-21 2017-04-18 Селлзоум Лимитед Морфолино-замещенные производные мочевины или карбамата в качестве ингибиторов mtor
BR112014008241A2 (pt) 2011-10-07 2017-04-18 Cellzome Ltd composto, composição farmacêutica, métodos para tratar, controlar, retardar ou prevenir doenças e distúrbios, e para preparar um composto, e, uso de um composto
CN102499917B (zh) 2011-10-25 2014-12-17 澳门大学 吲哚酮类化合物在制备神经保护药物中的应用
KR20140090218A (ko) 2011-10-28 2014-07-16 노파르티스 아게 신규 퓨린 유도체 및 질환의 치료에서의 그의 용도
CN103130774B (zh) * 2011-11-22 2016-06-22 齐鲁制药有限公司 具有酪氨酸激酶抑制作用的化合物及其制备方法和应用
CN103127096B (zh) * 2011-12-02 2015-11-25 杨子娇 吡咯基取代的吲哚类化合物在治疗青光眼病的应用
EP2794598A1 (en) 2011-12-23 2014-10-29 Cellzome Limited Pyrimidine-2,4-diamine derivatives as kinase inhibitors
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
CN102491932A (zh) * 2011-12-26 2012-06-13 天津科技大学 一种3-吲哚啉酮类衍生物及其制备方法及其应用
WO2013140232A1 (en) 2012-03-23 2013-09-26 Laurus Labs Private Limited An improved process for the preparation of sunitinib and its acid addition salts thereof
KR101774861B1 (ko) 2012-04-20 2017-09-05 안지 파마슈티컬 코퍼레이션 리미티드 퓨린 유도체의 사이클로프로판카르복실레이트 에스터
PL399027A1 (pl) 2012-04-27 2013-10-28 Instytut Farmaceutyczny Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu
CN102653521B (zh) * 2012-04-27 2014-08-06 首都师范大学 吲哚-2-酮的哌嗪硫代甲酰肼衍生物及其制备方法和用途
NZ701324A (en) 2012-05-04 2016-09-30 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
HK1202435A1 (en) 2012-05-16 2015-10-02 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
ES2718478T3 (es) 2012-06-08 2019-07-02 Sutro Biopharma Inc Anticuerpos que comprenden restos de aminoácidos no naturales de localización específica, métodos para su preparación y métodos para su uso
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
US9238644B2 (en) 2012-08-17 2016-01-19 Cancer Therapeutics Crc Pty Limited VEGFR3 inhibitors
WO2014031566A1 (en) 2012-08-22 2014-02-27 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
AU2013308494B2 (en) 2012-08-31 2018-03-01 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
WO2014041349A1 (en) 2012-09-12 2014-03-20 Cancer Therapeutics Crc Pty Ltd Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
WO2014045101A1 (en) 2012-09-21 2014-03-27 Cellzome Gmbh Tetrazolo quinoxaline derivatives as tankyrase inhibitors
EP2909181B1 (en) 2012-10-16 2017-08-09 Tolero Pharmaceuticals, Inc. Pkm2 modulators and methods for their use
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
MX2015004979A (es) 2012-12-21 2015-07-17 Eisai R&D Man Co Ltd Forma amorfa de derivado de quinolina y metodo para su produccion.
EP2961434A2 (en) 2013-02-28 2016-01-06 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
JP6423804B2 (ja) 2013-02-28 2018-11-14 イミュノジェン・インコーポレーテッド 細胞結合剤及び細胞毒性剤を含む複合体
BR112015022431A2 (pt) * 2013-03-13 2017-05-09 Boston Biomedical Inc derivados de 3-(aril ou heteroaril) metilenoindolin-2-ona como inibidores de quinases da via de sinalização de células-tronco cancerosas para o tratamento de câncer
JP6433974B2 (ja) 2013-03-14 2018-12-05 トレロ ファーマシューティカルズ， インコーポレイテッド Ｊａｋ２およびａｌｋ２阻害剤およびその使用方法
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
AR095443A1 (es) 2013-03-15 2015-10-14 Fundación Centro Nac De Investig Oncológicas Carlos Iii Heterociclos condensados con acción sobre atr
US9206188B2 (en) 2013-04-18 2015-12-08 Arrien Pharmaceuticals Llc Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
CN104119321B (zh) * 2013-04-28 2017-09-08 齐鲁制药有限公司 二氢吲哚酮衍生物的二马来酸盐及其多晶型物
NZ714049A (en) 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
ES2865473T3 (es) 2013-07-10 2021-10-15 Sutro Biopharma Inc Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
FR3008411B1 (fr) * 2013-07-12 2015-07-03 Servier Lab Nouveau sel de la 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione, sa preparation, et les formulations qui le contiennent
DK3039424T3 (da) 2013-08-28 2020-08-31 Crown Bioscience Inc Taicang Genekspressionssignaturer, der er prædiktive for et individs respons på en multikinaseinhibitor, og fremgangsmåder til anvendelse af disse
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
CA2838587A1 (en) 2013-10-18 2015-04-18 Hari Babu Matta Pure crystalline form ii of l-malic acid salt of sunitinib and processes for its preparation
US9278955B2 (en) 2013-10-18 2016-03-08 Sun Pharmaceutical Industries Limited Ascorbic acid salt of sunitinib
MY196581A (en) 2013-11-01 2023-04-19 Pfizer Vectors for Expression of Prostate-Associated Antigens
MX378409B (es) 2013-12-06 2025-03-10 Novartis Ag Regimen de dosificacion para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa.
CN104829596B (zh) * 2014-02-10 2017-02-01 石家庄以岭药业股份有限公司 吡咯取代吲哚酮类衍生物、其制备方法、包含该衍生物的组合物、及其用途
CN103923014A (zh) * 2014-05-05 2014-07-16 宁夏宝马药业有限公司 环肌酸制备方法
JP2017524034A (ja) 2014-08-08 2017-08-24 フォーサイト・ビジョン フォー・インコーポレーテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ４， Ｉｎｃ． 受容体型チロシンキナーゼ阻害剤の安定で可溶な製剤およびその調製の方法
CN113683564A (zh) 2014-08-28 2021-11-23 卫材R&D管理有限公司 高纯度喹啉衍生物及其生产方法
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
SG11201705767PA (en) 2015-01-13 2017-08-30 Univ Kyoto Agent for preventing and/or treating amyotrophic lateral sclerosis
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
CA2978226C (en) 2015-03-04 2025-02-18 Eisai R&D Management Co., Ltd. COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR TO TREAT CANCER
WO2016172214A1 (en) 2015-04-20 2016-10-27 Tolero Pharmaceuticals, Inc. Predicting response to alvocidib by mitochondrial profiling
WO2016184793A1 (en) 2015-05-15 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating a patient with vegfr inhibitor-resistant metastatic renal cell carcinoma
RU2752729C2 (ru) 2015-05-18 2021-07-30 Сумитомо Даиниппон Фарма Онколоджи, Инк. Пролекарства альвоцидиба, имеющие повышенную биодоступность
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
CN107801379B (zh) 2015-06-16 2021-05-25 卫材R&D管理有限公司 抗癌剂
JP7083497B2 (ja) 2015-08-03 2022-06-13 スミトモ ファーマ オンコロジー， インコーポレイテッド がんの処置のための併用療法
RU2718048C2 (ru) 2015-08-20 2020-03-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
MA42953A (fr) 2015-09-22 2018-08-01 Graybug Vision Inc Composés et compositions pour le traitement de troubles oculaires
GB2543550A (en) 2015-10-21 2017-04-26 Hox Therapeutics Ltd Peptides
WO2017077445A1 (en) 2015-11-02 2017-05-11 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
BR112018009644A2 (pt) 2015-11-12 2018-11-06 Graybug Vision Inc micropartículas agregantes sólidas modificadas na superfície, material injetável, processo para preparação de micropartículas agregantes sólidas modificadas na superfície, método para tratamento de um distúrbio ocular, e, uso de micropartículas agregantes sólidas modificadas na superfície
CA3011455A1 (en) 2016-01-27 2017-08-03 Sutro Biopharma, Inc. Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
JP2019508405A (ja) 2016-02-08 2019-03-28 ヴィトリサ セラピューティクス， インコーポレイテッド 改良された硝子体内半減期を有する組成物およびその使用
EP3228630A1 (en) 2016-04-07 2017-10-11 IMBA-Institut für Molekulare Biotechnologie GmbH Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer
CN107459519A (zh) 2016-06-06 2017-12-12 上海艾力斯医药科技有限公司 稠合嘧啶哌啶环衍生物及其制备方法和应用
WO2018045379A1 (en) 2016-09-02 2018-03-08 Dana-Farber Cancer Institute, Inc. Composition and methods of treating b cell disorders
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
EP3532464A4 (en) 2016-10-28 2020-07-08 Icahn School of Medicine at Mount Sinai COMPOSITIONS AND METHODS FOR THE TREATMENT OF EZH2 MEDIATION CANCER
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
KR102495436B1 (ko) 2016-12-05 2023-02-02 에이프로스 테라퓨틱스, 인크. 산성 기를 함유하는 피리미딘 화합물
US10786502B2 (en) 2016-12-05 2020-09-29 Apros Therapeutics, Inc. Substituted pyrimidines containing acidic groups as TLR7 modulators
AU2017370694A1 (en) 2016-12-08 2019-07-25 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating CDK4/6-mediated cancer
US10132797B2 (en) 2016-12-19 2018-11-20 Tolero Pharmaceuticals, Inc. Profiling peptides and methods for sensitivity profiling
WO2018147275A1 (ja) 2017-02-08 2018-08-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
CN106916143B (zh) * 2017-03-14 2019-09-27 哈尔滨医科大学 一种预防和治疗冠心病的药物及其应用
WO2018175922A1 (en) 2017-03-23 2018-09-27 Graybug Vision, Inc. Drugs and compositions for the treatment of ocular disorders
CN111201040A (zh) 2017-05-10 2020-05-26 灰色视觉公司 用于医学疗法的缓释微粒及其悬浮液
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы
WO2019023316A1 (en) 2017-07-26 2019-01-31 Sutro Biopharma, Inc. METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN THE TREATMENT OF A T CELL LYMPHOMA
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
AU2018333945B2 (en) 2017-09-18 2025-06-12 Sutro Biopharma, Inc. Anti- folate receptor alpha antibody conjugates and their uses
US20200237766A1 (en) 2017-10-13 2020-07-30 Tolero Pharmaceuticals, Inc. Pkm2 activators in combination with reactive oxygen species for treatment of cancer
NL2019801B1 (en) 2017-10-25 2019-05-02 Univ Leiden Delivery vectors
AU2019231689A1 (en) 2018-03-06 2020-09-24 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (AKT) degradation / disruption compounds and methods of use
EP3539536A1 (en) 2018-03-15 2019-09-18 MH10 Spolka z ograniczona odpowiedzialnoscia A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i
WO2020216450A1 (en) 2019-04-25 2020-10-29 Synthon B.V. Pharmaceutical composition comprising amorphous sunitinib
JP7351859B2 (ja) 2018-06-04 2023-09-27 アプロス セラピューティクス， インコーポレイテッド Ｔｌｒ７の調節に関係する疾患を処置するのに有用な酸性基を含むピリミジン化合物
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
CA3104298A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
AU2019310590A1 (en) 2018-07-26 2021-01-14 Sumitomo Pharma Oncology, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
EP3852811A1 (en) 2018-09-17 2021-07-28 Sutro Biopharma, Inc. Combination therapies with anti-folate receptor antibody conjugates
CN113490499A (zh) 2018-12-04 2021-10-08 大日本住友制药肿瘤公司 用作治疗癌症的活性剂的cdk9抑制剂及其多晶型物
CN113195000A (zh) 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合
CA3127502A1 (en) 2019-02-12 2020-08-20 Sumitomo Dainippon Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
US11793802B2 (en) 2019-03-20 2023-10-24 Sumitomo Pharma Oncology, Inc. Treatment of acute myeloid leukemia (AML) with venetoclax failure
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子
JP7547360B2 (ja) 2019-03-22 2024-09-09 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｐｋｍ２モジュレーターを含む組成物およびそれを使用する処置の方法
KR102861189B1 (ko) 2019-03-28 2025-09-16 앰플리아 테라퓨틱스 리미티드 Fak 억제제의 염 및 결정 형태
US20220362394A1 (en) 2019-05-03 2022-11-17 Sutro Biopharma, Inc. Anti-bcma antibody conjugates
CA3137916A1 (en) * 2019-05-06 2020-11-12 Ichan School Of Medicine At Mount Sinai Heterobifunctional compounds as degraders of hpk1
US20220298143A1 (en) 2019-08-31 2022-09-22 Etern Biopharma (Shanghai) Co., Ltd. Pyrazole Derivatives for FGFR Inhibitor and Preparation Method Thereof
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021178597A1 (en) 2020-03-03 2021-09-10 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
CN111233841A (zh) * 2020-03-17 2020-06-05 湖北扬信医药科技有限公司 一种舒尼替尼有关物质及其制备方法和用途
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
JP7633786B2 (ja) * 2020-09-18 2025-02-20 日本化薬株式会社 スニチニブリンゴ酸塩を有効成分とする医薬錠剤
US20240293365A1 (en) * 2021-06-28 2024-09-05 The Regents Of The University Of California Methods for treating and ameliorating t cell related diseases
CN113717159A (zh) * 2021-09-16 2021-11-30 中国药科大学 吲哚酮类化合物及其药物组合物、制备方法及用途
IL312506A (en) 2021-11-08 2024-07-01 Progentos Therapeutics Inc Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
EP4531927A1 (en) 2022-05-24 2025-04-09 Daiichi Sankyo Company, Limited Dosage regimen of an anti-cdh6 antibody-drug conjugate
CA3259758A1 (en) 2022-06-30 2024-01-04 Sutro Biopharma, Inc. Anti-ROR1 antibodies and antibody conjugates, compositions comprising anti-ROR1 antibodies or antibody conjugates, and methods of manufacturing and using anti-ROR1 antibodies and antibody conjugates
CN119233974A (zh) * 2022-07-22 2024-12-31 康百达（四川）生物医药科技有限公司 一种吲哚酮衍生物及其应用
CN118221652B (zh) * 2022-12-19 2025-06-06 沈阳药科大学 一种吲哚-2-酮衍生物及其制备方法和用途
WO2024188282A1 (zh) * 2023-03-14 2024-09-19 康百达（四川）生物医药科技有限公司 吲哚酮衍生物及其在医药上的应用
WO2025081117A2 (en) 2023-10-13 2025-04-17 Sutro Biopharma, Inc. Anti-tissue factor antibodies and antibody conjugates, compositions comprising anti-tissue factor antibodies or antibody conjugates, and methods of making and using anti-tissue factor antibodies and antibody conjugates
WO2025250825A1 (en) 2024-05-30 2025-12-04 Sutro Biopharma, Inc. Anti-trop2 antibodies, compositions comprising anti-trop2 antibodies and methods of making and using anti-trop2 antibodies
WO2025253311A1 (en) 2024-06-04 2025-12-11 Hetero Labs Limited 1,2-dicarboxamide compounds as kinase inhibitors

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL104796C (OSRAM) 1957-08-19
DE878539C (de) 1939-08-17 1953-06-05 Hoechst Ag Verfahren zur Herstellung von Methinfarbstoffen
BE507136A (OSRAM) 1950-11-18
BE553661A (OSRAM) 1955-12-23
NL96047C (OSRAM) 1956-06-08
NL251055A (OSRAM) 1959-04-29
FR1398224A (fr) 1964-05-06 1965-05-07 Ici Ltd Procédé de teinture de matières textiles de polyacrylonitrile
US3308134A (en) 1965-10-22 1967-03-07 Mcneilab Inc Spiro(indan-2, 3'-indoline)-1, 2'-diones
US3551571A (en) 1967-05-19 1970-12-29 Endo Lab Methods for reducing pain,reducing fever and alleviating inflammatory syndromes with heteroaromatic pyrrol-3-yl ketones
US3564016A (en) 1968-03-07 1971-02-16 Endo Lab Method of decarbonylation
US4070366A (en) 1968-06-12 1978-01-24 Canadian Patents & Development Limited Alkylation process
FR1599772A (OSRAM) 1968-09-17 1970-07-20
US3922163A (en) 1970-01-30 1975-11-25 Upjohn Co Organic compounds and process
US3715364A (en) 1970-12-28 1973-02-06 Merck & Co Inc Nitroimidazole carboxamides
DE2159361A1 (de) 1971-11-30 1973-06-14 Bayer Ag Nitrofuranderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2159363A1 (de) 1971-11-30 1973-06-14 Bayer Ag Antimikrobielle mittel
DE2159360A1 (de) 1971-11-30 1973-06-14 Bayer Ag Nitrofuranderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
DE2159362A1 (de) 1971-11-30 1973-06-14 Bayer Ag Nitrofuranderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
GB1384599A (en) 1972-05-04 1975-02-19 Colgate Palmolive Co Coloured detergent compositions
US3880871A (en) 1973-09-27 1975-04-29 Squibb & Sons Inc Isothiocyanophenyl substituted imidazoles
US4002643A (en) 1975-06-27 1977-01-11 Mcneil Laboratories, Inc. Preparation of β-acyl pyrroles
US4002749A (en) 1975-08-12 1977-01-11 E. R. Squibb & Sons, Inc. Substituted indolinones
US4053613A (en) 1975-09-17 1977-10-11 E. R. Squibb & Sons, Inc. 1,3,thiazolinyl and 1,3 thiazinyl substituted indolinones
DE2855306A1 (de) 1978-12-21 1980-07-10 Boehringer Sohn Ingelheim Mittel zur senkung der herzfrequenz
GR73560B (OSRAM) 1979-02-24 1984-03-15 Pfizer
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4343923A (en) 1980-08-07 1982-08-10 Armstrong World Industries, Inc. Process for reducing the acid dye uptake of polyamide textile materials with N-acylimidazole compound
CH646956A5 (de) 1981-12-15 1984-12-28 Ciba Geigy Ag Imidazolide.
EP0095285A1 (en) 1982-05-21 1983-11-30 Sumitomo Chemical Company, Limited N-acylimidazoles, their production and use
US4493642A (en) 1982-12-27 1985-01-15 Bogdon Glendon J Orthodontic device and associated orthodontic method
DE3310891A1 (de) 1983-03-25 1984-09-27 Boehringer Mannheim Gmbh, 6800 Mannheim Neue indolinon-(2)-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte
US4489089A (en) 1983-04-06 1984-12-18 American Cyanamid Company Substituted N-[ω-(1H-imidazol-1-yl)alkyl]-amides
EP0124482B1 (de) 1983-04-29 1989-11-08 Ciba-Geigy Ag Neue Imidazolide und deren Verwendung als Härter für Polyepoxidverbindungen
DE3415138A1 (de) 1984-04-21 1985-10-31 Basf Ag, 6700 Ludwigshafen N-(azolylcarbamoyl)-hydroxylamine und diese enthaltende fungizide
DE3426419A1 (de) 1984-07-18 1986-01-23 Boehringer Mannheim Gmbh, 6800 Mannheim Neue oxindol-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte
US4560700A (en) 1985-02-08 1985-12-24 Merrell Dow Pharmaceuticals Inc. Pyrrole-3-carboxylate cardiotonic agents
JPS6229570A (ja) 1985-07-29 1987-02-07 Kanegafuchi Chem Ind Co Ltd ３，５−ジイソプロピルベンジリデン複素環式化合物
JPH078851B2 (ja) 1985-07-29 1995-02-01 鐘淵化学工業株式会社 ３−フエニルチオメチルスチレン誘導体
JPS6239564A (ja) 1985-08-13 1987-02-20 Kanegafuchi Chem Ind Co Ltd α−ベンジリデン−γ−ブチロラクトンまたはγ−ブチロラクタム誘導体
US4966849A (en) 1985-09-20 1990-10-30 President And Fellows Of Harvard College CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression
WO1993012786A1 (en) 1986-07-10 1993-07-08 Howard Harry R Jr Indolinone derivatives
US4853404A (en) 1986-10-13 1989-08-01 Tanabe Seiyaku Co., Ltd. Phenoxyacetic acid derivatives composition and use
JPS63141955A (ja) 1986-12-03 1988-06-14 Kanegafuchi Chem Ind Co Ltd トリベンジルアミン誘導体
EP0304493B1 (en) 1987-03-11 1992-09-02 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Hydroxystyrene derivatives
US5089516A (en) 1987-03-11 1992-02-18 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha 1-phenyl-3,5-pyrazolidinedione hydroxystyrene compounds which have tyrosine kinase inhibiting activity
US5202341A (en) 1987-03-11 1993-04-13 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Hydroxystyrene compounds having tyrosine kinase inhibiting activity
US5043348A (en) 1987-04-24 1991-08-27 Cassella Aktiengesellschaft Pyrrolealdehydes, their preparation and their use
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
DE3808071A1 (de) 1988-03-11 1989-09-21 Basf Ag Verfahren zur herstellung von acylierten imidazolen
US4868304A (en) 1988-05-27 1989-09-19 Iowa State University Research Foundation, Inc. Synthesis of nitrogen heterocycles
CA1339784C (en) 1988-06-23 1998-03-31 Shinya Inoue Pyrrolecarboxylic acid derivatives
JPH06104658B2 (ja) 1988-06-23 1994-12-21 三菱化成株式会社 ピロールカルボン酸誘導体
GB8816944D0 (en) 1988-07-15 1988-08-17 Sobio Lab Compounds
DE3824658A1 (de) 1988-07-15 1990-01-18 Schering Ag N-hetaryl-imidazolderivate
US5084280A (en) 1988-12-15 1992-01-28 Chapman Chemical Company Wood preservation composition and method
DE3902439A1 (de) 1989-01-27 1990-08-02 Basf Ag Pflanzenschuetzende mittel auf basis von 1-aryl- bzw. 1-hetarylimidazolcarbonsaeureestern
US5047554A (en) 1989-04-18 1991-09-10 Pfizer Inc. 3-substituted-2-oxindole derivatives
ES2110965T3 (es) 1989-07-25 1998-03-01 Taiho Pharmaceutical Co Ltd Derivado de oxoindol.
US5258357A (en) 1989-10-07 1993-11-02 Basf Aktiengesellschaft Carboxamides, their preparation and their use as herbicides
CA2032421A1 (en) 1989-12-20 1991-06-21 Mitsubishi Chemical Corporation Pyrrolealdehyde derivative
GB9004483D0 (en) 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
CA2012634A1 (en) 1990-03-20 1991-09-20 Hassan Salari Tyrphostins for treatment of allergic, inflammatory and cardiovascular diseases
DE69105495T2 (de) 1990-04-02 1995-04-06 Pfizer Benzylphosphonsäure-tyrosinkinaseinhibitoren.
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
US5196446A (en) 1990-04-16 1993-03-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Certain indole compounds which inhibit EGF receptor tyrosine kinase
JP2944721B2 (ja) 1990-08-22 1999-09-06 生化学工業株式会社 エンドトキシンの測定剤
WO1992007830A2 (en) 1990-10-29 1992-05-14 Pfizer Inc. Oxindole peptide antagonists
IT1247509B (it) 1991-04-19 1994-12-17 Univ Cagliari Composti di sintesi atti all'impiego nella terapia delle infezioni da rhinovirus
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
EP0584222B1 (en) 1991-05-10 1997-10-08 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
EP0586608A1 (en) 1991-05-29 1994-03-16 Pfizer Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
GB9115160D0 (en) 1991-07-12 1991-08-28 Erba Carlo Spa Methylen-oxindole derivatives and process for their preparation
US5124347A (en) 1991-07-31 1992-06-23 Warner-Lambert Co. 3-5-ditertiarybutylphenyl-4-hydroxymethylidene derivatives of 1,3-dihydro-2H-indole-2-ones as antiinflammatory agents
JPH0558894A (ja) 1991-08-27 1993-03-09 Kanegafuchi Chem Ind Co Ltd 抗腫瘍剤
WO1993007751A1 (en) 1991-10-18 1993-04-29 Monsanto Company Fungicides for the control of take-all disease of plants
US5389661A (en) 1991-12-05 1995-02-14 Warner-Lambert Company Imidazole and 1,2,4-triazole derivatives with angiotensin II antagonist properties
US5322950A (en) 1991-12-05 1994-06-21 Warner-Lambert Company Imidazole with angiotensin II antagonist properties
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
FR2689397A1 (fr) 1992-04-01 1993-10-08 Adir Utilisation des dérivés de la 3-(3,5-Ditert-Butyl-4-Hydroxybenzylidenyl) Indoline-2-one pour l'obtention de médicaments.
DE4211531A1 (de) 1992-04-06 1993-10-07 Cassella Ag Verfahren zur Herstellung von Pyrrolderivaten
AU668180B2 (en) 1992-05-20 1996-04-26 Merck & Co., Inc. 17-ethers and thioethers of 4-aza-steroids
FR2694004B1 (fr) 1992-07-21 1994-08-26 Adir Nouvelles 3-(Hydroxybenzylidényl)-indoline-2-ones et 3-(hydroxybenzylidényl)-indoline-2-thiones, leurs procédés de préparation, et les compositions pharmaceutiques qui les contiennent.
JPH08503450A (ja) 1992-08-06 1996-04-16 ワーナー−ランバート・コンパニー 蛋白チロシンキナーゼを阻害し、かつ抗腫瘍特性を有する２−チオインドール（セレノインドール）および関連ジスルフィド（セレニド）
US5565324A (en) 1992-10-01 1996-10-15 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
WO1994010202A1 (en) 1992-10-28 1994-05-11 Genentech, Inc. Vascular endothelial cell growth factor antagonists
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
JP3507124B2 (ja) 1993-05-26 2004-03-15 塩野義製薬株式会社 ベンジリデン誘導体の製造法
EP0632102B1 (de) 1993-06-28 1997-04-02 Bayer Ag Massefärben von Kunststoffen
GB9313638D0 (en) 1993-07-01 1993-08-18 Erba Carlo Spa Arylidene and heteroarylidene oxindole derivatives and process for their preparation
US5332736A (en) 1993-11-01 1994-07-26 Ortho Pharmaceutical Corporation Anti-convulsant aroyl aminoacylpyrroles
US5502072A (en) 1993-11-26 1996-03-26 Pfizer Inc. Substituted oxindoles
GB9326136D0 (en) 1993-12-22 1994-02-23 Erba Carlo Spa Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
US5610173A (en) 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9412719D0 (en) 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
GB9423997D0 (en) 1994-11-28 1995-01-11 Erba Carlo Spa Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
GB9507298D0 (en) 1995-04-07 1995-05-31 Pharmacia Spa Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5786488A (en) 1996-11-13 1998-07-28 Sugen, Inc. Synthetic methods for the preparation of indolyquinones
JP3246712B2 (ja) 1995-11-15 2002-01-15 株式会社トクヤマ エテニルアミド化合物の製造方法
DE69722858T2 (de) 1996-01-17 2004-05-13 Taiho Pharmaceutical Co. Ltd. Intimale verdickungsinhibitoren
EP0788890A1 (en) 1996-02-06 1997-08-13 Agfa-Gevaert N.V. Dyes and dye-donor elements for thermal dye transfer recording
AU2066797A (en) 1996-03-21 1997-10-10 Sugen, Inc. Assays for kdr/flk-1 receptor tyrosine kinase inhibitors
NZ325914A (en) 1996-03-29 1999-09-29 Pfizer Benzyl(idene)-lactam derivatives and salts thereof, their preparation and their use as selective (ant)agonists of 5-ht1a and/or 5-ht1d receptors and thus are effective as psychotherapeutic agents
CA2206201A1 (en) 1996-05-29 1997-11-29 Yoshiaki Isobe Pyrazole derivatives and their pharmaceutical use
AU3767997A (en) 1996-08-01 1998-02-25 Merckle Gmbh Acylpyrroldicarboxylic acids and acylindoldicarboxylic acids and their derivatives and inhibitors of the cytosolic phospholipase a2
CA2263838A1 (en) 1996-08-21 1998-02-26 Sugen, Inc. Crystal structures of a protein tyrosine kinase
JP2001503736A (ja) 1996-08-23 2001-03-21 スージェン・インコーポレーテッド 疾病の治療のためのインドリノンのコンビナトリアルライブラリーおよび関連する生成物および方法
AU7622698A (en) 1996-12-05 1998-06-29 Sugen, Inc. Use of indolinone compounds as modulators of protein kinases
ATE554750T1 (de) 1997-03-05 2012-05-15 Sugen Inc Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
WO1998045708A1 (en) 1997-04-08 1998-10-15 Sugen, Inc. Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
WO1998050356A1 (en) * 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
AU8071698A (en) 1997-06-13 1998-12-30 Sugen, Inc. Novel heteroaryl compounds for the modulation of protein tyrosine enzyme relatedcellular signal transduction
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6133305A (en) 1997-09-26 2000-10-17 Sugen, Inc. 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity
UA58476C2 (uk) 1997-10-09 2003-08-15 Санофі-Сентелябо Похідні 8-азабіцикло[3.2.1]октан-3-метанаміну, фармацевтична композиція та лікарський засіб
WO1999048868A2 (en) 1998-03-26 1999-09-30 Sugen, Inc. Heterocyclic classes of compounds for the modulating tyrosine protein kinase
DE19816624A1 (de) 1998-04-15 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel
IL139934A (en) * 1998-05-29 2007-10-31 Sugen Inc History 2 - Indulinone converted to pyrrole and pharmaceutical preparations containing them
DE19826940A1 (de) 1998-06-17 1999-12-23 Bayer Ag Substituierte N-Aryl-O-alkyl-carbamate
JP2002522452A (ja) 1998-08-04 2002-07-23 スージェン・インコーポレーテッド 蛋白質キナーゼの調節剤３−メチリデニル−２−インドリノン
US6462072B1 (en) 1998-09-21 2002-10-08 Gpi Nil Holdings, Inc. Cyclic ester or amide derivatives
CN1526448A (zh) 1998-12-14 2004-09-08 ���ռ�ҩ��ɷ����޹�˾ 用于治疗肛门直肠病的药物和方法
DK1157019T3 (da) * 1998-12-17 2003-07-14 Hoffmann La Roche 4-alkenyl- (og alkynyl-)oxindoler som inhibitorer af cyklinafhængige kinaser, især CDK2
US6284894B1 (en) 1998-12-18 2001-09-04 Nycomed Imaging As Preparation of allylic aromatic compounds
AU760964B2 (en) * 1998-12-31 2003-05-22 Sugen, Inc. 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activityand for use in cancer chemotherapy
WO2000056709A1 (en) 1999-03-24 2000-09-28 Sugen, Inc. Indolinone compounds as kinase inhibitors
ES2367007T3 (es) * 1999-11-24 2011-10-27 Sugen, Inc. Derivados de indolinona ionizables y su uso como ligandos de ptk.
US20020010203A1 (en) * 1999-12-22 2002-01-24 Ken Lipson Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
RS50444B (sr) 2000-02-15 2010-03-02 Sugen Inc. Inhibitori 2-indolinon protein kinaze supstituisani pirolom
MY128449A (en) 2000-05-24 2007-02-28 Sugen Inc Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
WO2002002551A1 (en) * 2000-06-30 2002-01-10 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
CA2432114A1 (en) * 2000-12-20 2002-07-18 Sugen, Inc. 4-(hetero)aryl substituted indolinones

Also Published As

Publication number Publication date
DK1255752T3 (da) 2007-11-26
NL300430I2 (nl) 2010-04-01
WO2001060814A2 (en) 2001-08-23
EA005996B1 (ru) 2005-08-25
LU91407I9 (OSRAM) 2018-12-28
PT1255752E (pt) 2007-10-17
AU3977001A (en) 2001-08-27
BG107078A (bg) 2003-04-30
SK287142B6 (sk) 2010-01-07
CY2008004I2 (el) 2009-11-04
IL151127A0 (en) 2003-04-10
BRPI0117360A2 (pt) 2012-01-24
EA200200862A1 (ru) 2003-02-27
NO20023831L (no) 2002-10-15
DE122008000002I1 (de) 2008-04-17
HUP0204433A3 (en) 2007-08-28
NL300430I1 (nl) 2010-03-01
CO5280092A1 (es) 2003-05-30
HK1051188A1 (en) 2003-07-25
FR08C0002I2 (fr) 2009-01-02
BRPI0117360B8 (pt) 2021-07-06
BR0108394A (pt) 2004-06-22
CA2399358C (en) 2006-03-21
LU91407I2 (fr) 2008-03-10
JP2003523340A (ja) 2003-08-05
BE2010C009I2 (OSRAM) 2020-01-30
US20070010569A1 (en) 2007-01-11
CA2399358A1 (en) 2001-08-23
CY1108032T1 (el) 2011-04-06
KR20030003229A (ko) 2003-01-09
CN1329390C (zh) 2007-08-01
FR10C0003I2 (fr) 2012-06-22
US7125905B2 (en) 2006-10-24
US20050176802A1 (en) 2005-08-11
HRP20020751A2 (en) 2004-12-31
JP3663382B2 (ja) 2005-06-22
LTPA2008002I1 (lt) 2019-02-25
AU2001239770B2 (en) 2006-01-05
CY2010004I1 (el) 2012-01-25
WO2001060814A3 (en) 2002-01-24
CR20120007A (es) 2012-02-24
FR10C0003I1 (fr) 2010-03-05
EP1255752A2 (en) 2002-11-13
YU61402A (sh) 2005-07-19
US6573293B2 (en) 2003-06-03
FR08C0002I1 (OSRAM) 2008-03-21
CZ303705B6 (cs) 2013-03-27
SK13262002A3 (sk) 2003-03-04
ATE369359T1 (de) 2007-08-15
CN1439005A (zh) 2003-08-27
US20040063773A1 (en) 2004-04-01
PE20011083A1 (es) 2001-10-26
NO325532B1 (no) 2008-06-09
UA73976C2 (uk) 2005-10-17
IS6501A (is) 2002-08-13
DE60129794T2 (de) 2007-12-06
MXPA02008021A (es) 2004-04-05
ES2290117T3 (es) 2008-02-16
NL300332I1 (nl) 2008-03-03
NO20023831D0 (no) 2002-08-13
LTC1255752I2 (lt) 2019-08-26
NO2010002I1 (no) 2010-03-08
NZ520640A (en) 2005-04-29
DE122010000004I1 (de) 2010-04-15
BRPI0108394B8 (pt) 2021-05-25
DE60129794D1 (de) 2007-09-20
US20020156292A1 (en) 2002-10-24
NO2008019I1 (no) 2009-01-12
PL211834B1 (pl) 2012-06-29
LU91657I2 (fr) 2010-05-03
PL361209A1 (en) 2004-09-20
HRP20020751B1 (hr) 2011-01-31
RS50444B (sr) 2010-03-02
CZ20023081A3 (cs) 2003-02-12
AR034118A1 (es) 2004-02-04
BG65764B1 (bg) 2009-10-30
ME00415B (me) 2011-10-10
TWI306860B (en) 2009-03-01
BRPI0117360B1 (pt) 2018-11-13
SI1255752T1 (sl) 2007-12-31
CY2008004I1 (el) 2009-11-04
EP1255752B1 (en) 2007-08-08
NO2019005I1 (no) 2019-02-11
KR100713960B1 (ko) 2007-05-02
MY130363A (en) 2007-06-29
NO2010002I2 (no) 2010-12-06
NL300332I2 (nl) 2008-04-01
CY2010004I2 (el) 2012-01-25
NO2008019I2 (no) 2011-10-17
IS2491B (is) 2009-01-15
HU228979B1 (en) 2013-07-29
BRPI0108394B1 (pt) 2018-12-11
US7572924B2 (en) 2009-08-11
HUP0204433A2 (hu) 2003-04-28

Similar Documents

Publication Publication Date Title
CR20120009A (es) 2-indolinonas sustituidas con pirrolos inhibidores de proteinquinasas (divisional exp. 6728)
CR7056A (es) Derivados de 3-(4-amidopirrol-2-ilmetilden)-2-indolinona como inhibidores de la protein quinasa
ECSP941122A (es) Derivados de 5-arilindoles
CO5271715A1 (es) 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
PA8493701A1 (es) Compuestos para tratar la obesidad
ECSP003682A (es) Compuestos para el tratamiento de la isquemia
ES2191187T3 (es) Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosin-quinasa.
ES2196072T3 (es) Empleo de compuestos heterociclicos como ligandos de dopamina-d3.
GT199900070A (es) Derivados de isotiazol, utiles como agentes anticancerosos.
PA8550101A1 (es) Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células, y métodos para su utilización
MXPA05012573A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa.
UY26231A1 (es) Compuestos de indazol y composiciones farmaceuticas para la inhibicion de proteina kinasa y metodo para su uso. bajo ley 17.164
ATE292623T1 (de) 2-indolinonderivate als modulatoren der proteinkinase-ativität
GT200100061A (es) Compuestos y composiciones farmaceuticas y metodos para inhibir kinasas proteinicas.
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
CO4810373A1 (es) Compuestos azapoliciclicos condensados con arilo
SV2002000096A (es) Compuestos tiazole y composiciones farmaceuticas pra inhibir la proteina kinases y metodo para su uso caso no. 0125-0024sv
DOP2004000949A (es) Derivados de pirrolo [3,4-c]pirazol activos como inhibidores de cinasa, proceso para su preparacion y composiciones farmaceuticas que comprenden los mismos
GT200300294A (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
ECSP045473A (es) Derivados de 1-(aminoalquil)-3-sulfonilindol y 1-aminoalquil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6
PA8555501A1 (es) Compuestos de benzimidazol sustituido y su uso para el tratamiento del cancer
ECSP066763A (es) Pirazolopirimidinas novedosas como inhibidores de quinasa ciclina-dependientes
UY27232A1 (es) Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
GT200500020A (es) Derivados de 1h-tieno[2,3-c]pirazol utiles como inhibidores de quinasa.